127 related articles for article (PubMed ID: 38389494)
1. LaSap vaccine: Immunotherapy and immunochemotherapy associated with allopurinol in dogs naturally infected with Leishmania infantum.
Clasta RB; Rivas AV; Souza AB; Dos Santos AGV; Le Quesne AHM; Gonçalves AAM; Cangussu ASR; Giunchetti RC; Viana KF
Parasite Immunol; 2024 Feb; 46(2):e13028. PubMed ID: 38389494
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic vaccine of killed Leishmania amazonensis plus saponin reduced parasite burden in dogs naturally infected with Leishmania infantum.
Viana KF; Lacerda G; Teixeira NS; Rodrigues Cangussu AS; Sousa Aguiar RW; Giunchetti RC
Vet Parasitol; 2018 Apr; 254():98-104. PubMed ID: 29657019
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.
Cardoso JMO; Brito RCF; Mathias FAS; Reis LES; Vieira JFP; Ostolin TLVDP; Andrade HM; Ramos GS; Frézard F; Aguiar-Soares RDO; Roatt BM; Reis AB
Mol Immunol; 2022 Jan; 141():70-78. PubMed ID: 34814056
[TBL] [Abstract][Full Text] [Related]
5. Potential of Artesunate in the treatment of visceral leishmaniasis in dogs naturally infected by Leishmania infantum: Efficacy evidence from a randomized field trial.
Medkour H; Bitam I; Laidoudi Y; Lafri I; Lounas A; Hamidat HK; Mekroud A; Varloud M; Davoust B; Mediannikov O
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008947. PubMed ID: 33338041
[TBL] [Abstract][Full Text] [Related]
6. Canine Leishmania vaccines: still a long way to go.
Gradoni L
Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.
Dos Santos CCP; Ramos GS; De Paula RC; Faria KF; Moreira POL; Pereira RA; Melo MN; Tafuri WL; Demicheli C; Ribeiro RR; Azevedo EG; Do Monte-Neto R; Da Silva SM; Frézard F
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284386
[TBL] [Abstract][Full Text] [Related]
8. Periodic administration of allopurinol is not effective for the prevention of canine leishmaniosis (Leishmania infantum) in the endemic areas.
Saridomichelakis MN; Mylonakis ME; Leontides LS; Billinis C; Koutinas AF; Galatos AD; Gouletsou P; Diakou A; Kontos VI
Vet Parasitol; 2005 Jun; 130(3-4):199-205. PubMed ID: 15905034
[TBL] [Abstract][Full Text] [Related]
9. Acute-phase proteins in dogs naturally infected with Leishmania infantum during and after long-term therapy with allopurinol.
Sasanelli M; Paradies P; de Caprariis D; Greco B; De Palo P; Palmisano D; Carelli G
Vet Res Commun; 2007 Aug; 31 Suppl 1():335-8. PubMed ID: 17682908
[No Abstract] [Full Text] [Related]
10. Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.
Ferreira JH; Silva Ldos S; Longo-Maugéri IM; Katz S; Barbiéri CL
PLoS Negl Trop Dis; 2014 Mar; 8(3):e2729. PubMed ID: 24625516
[TBL] [Abstract][Full Text] [Related]
11. Clinical and parasitological impact of short-term treatment using miltefosine and allopurinol monotherapy or combination therapy in canine visceral leishmaniasis.
Ayres EDCBS; Dias ÁFLR; Monteiro BRG; Pazzini SS; Barbosa MEC; Silva EBD; Macedo LFDC; Sousa VRF; Dutra V; Nakazato L; Almeida ADBPF
Rev Bras Parasitol Vet; 2022; 31(3):e007222. PubMed ID: 35920471
[TBL] [Abstract][Full Text] [Related]
12. Current status on prevention and treatment of canine leishmaniasis.
Reguera RM; Morán M; Pérez-Pertejo Y; García-Estrada C; Balaña-Fouce R
Vet Parasitol; 2016 Aug; 227():98-114. PubMed ID: 27523945
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of the use of miltefosine, miltefosine plus allopurinol, and allopurinol in dogs with visceral leishmaniasis.
Dias ÁFLR; Ayres EDCBS; de Oliveira Martins DT; Maruyama FH; de Oliveira RG; de Carvalho MR; Almeida ADBPF; Teixeira ALS; Mendonça AJ; Sousa VRF
Exp Parasitol; 2020 Oct; 217():107947. PubMed ID: 32628971
[TBL] [Abstract][Full Text] [Related]
14. Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum.
Cavaliero T; Arnold P; Mathis A; Glaus T; Hofmann-Lehmann R; Deplazes P
J Vet Intern Med; 1999; 13(4):330-4. PubMed ID: 10449224
[TBL] [Abstract][Full Text] [Related]
15. Down regulation of IL-10 and TGF-β1 mRNA expression associated with reduced inflammatory process correlates with control of parasitism in the liver after treatingL. infantuminfected dogs with the LBMPL vaccine therapy.
Mendes Roatt B; Mirelle de Oliveira Cardoso J; Cristiane Fortes de Brito R; Eduardo Soares Reis L; José Lucas Moreira G; Melo de Abreu Vieira P; Marques de Souza F; Geraldo de Lima W; Dian de Oliveira Aguiar-Soares R; Cordeiro Giunchetti R; Barbosa Reis A
Cytokine; 2022 May; 153():155838. PubMed ID: 35259630
[TBL] [Abstract][Full Text] [Related]
16. Leishmania infantum in a Central Italy dog shelter: retrospective study of serologic reactivity during a 4-year period in a confined dog population subjected to preventive and therapeutic treatment.
Podaliri Vulpiani M; Iannetti L; Di Mattia T; Dalla Villa P
Vet Parasitol; 2009 Mar; 160(3-4):190-7. PubMed ID: 19111991
[TBL] [Abstract][Full Text] [Related]
17. [Interpretation of laboratory data during cryptic leishmaniasis in dog].
Gravino AE
Parassitologia; 2004 Jun; 46(1-2):227-9. PubMed ID: 15305723
[TBL] [Abstract][Full Text] [Related]
18. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
[TBL] [Abstract][Full Text] [Related]
19. An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy.
Gonçalves AAM; Leite JC; Resende LA; Mariano RMDS; Silveira P; Melo-Júnior OAO; Ribeiro HS; de Oliveira DS; Soares DF; Santos TAP; Marques AF; Galdino AS; Martins-Filho OA; Dutra WO; da Silveira-Lemos D; Giunchetti RC
Front Cell Infect Microbiol; 2019; 9():427. PubMed ID: 31921703
[TBL] [Abstract][Full Text] [Related]
20. Hepatic fibropoiesis in dogs naturally infected with Leishmania (Leishmania) infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol.
Castro RS; de Amorim IFG; Pereira RA; Silva SM; Pinheiro LJ; Pinto AJW; Azevedo EG; Demicheli C; Caliari MMV; Mosser DM; Michalick MSM; Frezard FJG; Tafuri WL
Vet Parasitol; 2018 Jan; 250():22-29. PubMed ID: 29329619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
